Phenylpiracetam is widely believed to have first been created in Russia in the early 1990s, but Soviet journals from 1983 held information regarding it under the name of "Carphedron". Pharmacological studies have shown that Phenylpiracetam stimulates certain neuronal receptors in the Central Nervous System (CNS) that are involved in memory and thought processes, such as the acetylcholine transmitters, GABA receptors, and NDMA receptors. Phenylpiracetam has also shown to increase dopamine receptors (D1, D2, and D3) activity.Carphedon
Phenylpiracetam, is a Phenylpiracetam product with nootropic* effects. Experimental studies have proved it to be effective in improving memory and learning capacity.
This medicine has a sedative effect, which does not influence the activity of the autonomous nervous system. Its action is mildly disinhibitory and antidepressant.Phenylpiracetam is a nootropic drug derived from piracetam, and is more potent (i.e. lower dosage is used). It belongs to the racetam family of nootropics. Phenylpiraceta was developed by Parke-Davis based on Piracetam, and is 8-30 times stronger than Piracetam.